APOLIPOPROTEIN CS AS MARKERS OF CARDIOVASCULAR RISK AND METABOLIC SYNDROME, WITH PARTICULAR REFERENCE TO APO C-III

Abstract
Apolipoprotein (apo) Cs, protein constituents of chylomicrons, VLDL and HDL, have an inhibitory or stimulatory effect on various receptors and enzymes involved in lipoprotein metabolism. Studies revealed raised coronary risk and induced myocardial ischemia associated with high levels of apoC-III in apoB-containing lipoproteins. The relationship between levels of serum apoC-III or its distribution among HDL and nonHDL particles and prevalent coronary heart disease (CHD) or the metabolic syndrome was recently evaluated in the Turkish Adult Risk Factor study in 859 men and women. Strong associations existed between apoC-III in HDL and in apoB-containing lipoproteins on the one hand and lipid, nonlipid risk factors and inflammatory risk markers on the other. The age-adjusted hazard ratio for 1 SD (3 mg/dl) of nonHDL apoC-III was a significant 2.5-fold. In logistic regression models which included age and LDL-cholesterol, men in the upper quartile of nonHDL apoC-III, compared to the lowest quartile, showed an almost 9-fold prevalent CHD likelihood. In women, the tendency of apoC-III to be asssociated with CHD likelihood, was not independent of age or LDL-C.

Key words
Apolipoproteins, coronary heart disease, metabolic syndrome, risk assessment, risk factors

Artículo completo

Bibliografía del artículo

1. Jong MC, Hofker MH, Havekes LM. Role of apoCs in lipoprotein metabolism: functional differences between apoC1, apoC2, and apoC3. Arterioscler Thromb Vasc Biol 1999;19:472-84.
2. Weisgraber KH, Mahley RW, Kowall RC, et al. Apolipoprotein C-I modulates the interaction of apolipoprotein E with β-migrating very low density lipoproteins (-VLDL) and inhibits binding of VLDL to low density lipoprotein receptor-related protein. J Biol Chem 1990; 265:22453-9.
3. Sehayek E, Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem 1991; 266:18259-67.
4. Clavey V, Lestavel-Delattre S, Copin C, et al. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII and E. Arterioscler Thromb Vasc Biol 1995;15:963-71.
5. Mann CJ, Troussard AA, Yen FT, et al. Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor. J Biol Chem 1997; 272:31348-54.
6. Havel RJ, Fielding CJ, Olivecrona T, et al. Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoprotein lipase from different sources. Biochemistry 1973; 12:1828-33.
7. Soutar AK, Garner CW, Baker HN, et al. Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithine:cholesterol acyl transferase. Biochemistry 1975; 14:3057-64.
8. Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000; 102:1886-92.
9. Onat A, Hergenç G, Sansoy V, Fobker M, Ceyhan K, Toprak S, Assmann G: Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of adverse risk profile in both genders. Atherosclerosis 2003; 168:81-9.
10. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001; 156:1-10.
11. Nestel PJ, Fidge NH. Apoprotein C metabolism in man. Adv Lipid Res 1982; 19:55-83.
12. Sniderman A, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Int Med 2001; 135:447-59.
13. Wang C, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. J Clin Invest 1985; 75:384-90.
14. Onat A, Ceyhan K, Baar Ö, Erer B, Toprak S, Sansoy V: Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels – a prospective and cross-sectional evaluation. Atherosclerosis 2002; 165:285-292.
15. Thompson GR: Angiographic evidence for the role of triglyceride-rich lipoproteins in progression of coronary artery disease. Eur Heart J 1998: 19Suppl H:H31-6.
16. Lee S-J, Moye LA, Campos H, Williams GH, Sacks FM: Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease. Atherosclerosis 2003; 167:293-302.
17. Campos H, Perlov D, Khoo C, Sacks FM. Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia. J Lipid Res 2001; 42:1239-49.
18. Björkegren J, Boquist S, Samnegard A, et al. Accumulation od apolipoprotein C-I-rich and cholesterol-rich VLDL remnants during exaggerated postprandial triglyceridemia in normolipidemic patients with coronary artery disease. Circulation 2000; 101:227-30.
19. Björkegren J, Silveira A, Boquist S, et al. Postprandial enrichment of remnant lipoproteins with apoC-I in healthy normolipidemic men with early asymptomatic atherosclerosis. Arterioscler Thromb Vasc Biol 2002;22:1470.
20. Staels B, Vu-Dac N, Kosykh VA, et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase: a potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995;95:705-12.